自閉症スペクトラム障害治療の世界市場：薬剤タイプ別、用途別、流通チャネル別、地域別、機会、予測、2018年～2032年

世界の自閉症スペクトラム障害（ASD）治療の市場規模は、予測期間の2025年～2032年に6.87％のCAGRで拡大し、2024年の23億米ドルから2032年には39億1,000万米ドルに成長すると予測されています。市場は、自閉症スペクトラム障害（ASD）の認知度向上と早期診断が治療需要の増加を促しています。薬剤研究と臨床試験の進歩により、中核症状と関連症状の両方に対する治療選択肢が拡大しています。さらに、北米における小児症例の増加と強力な地域支援が引き続き市場拡大を後押ししています。

例えば、PaxMedicaは2024年6月に米国食品医薬品局（FDA）に新薬承認申請（NDA）を行う予定です。革新的な医薬品であるPAX-101のFDA承認を取得することで、同社はアンメット・メディカル・ニーズの高い市場で大きな存在感を示そうとしています。このアプローチは、同社の事業ポートフォリオの価値を高めるものと期待されています。

当レポートでは、世界の自閉症スペクトラム障害治療市場について調査し、市場の概要とともに、薬剤タイプ別、用途別、流通チャネル別、地域別動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 プロジェクトの範囲と定義

第2章 調査手法

第3章 米国の関税の影響

第4章 エグゼクティブサマリー

第5章 世界の自閉症スペクトラム障害治療市場の見通し、2018年～2032年

• 市場規模分析と予測
• 市場シェア分析と予測
  • 薬剤タイプ別
    • 抗精神病薬
    • 選択的セロトニン再取り込み阻害薬
    • 覚醒剤
    • 睡眠薬
    • その他
  • 用途別
    • 自閉症
    • アスペルガー症候群
    • 広汎性発達障害
    • その他
  • 流通チャネル別
    • 病院薬局
    • 小売薬局
    • オンライン薬局
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋
    • 南米
    • 中東・アフリカ
  • 企業別市場シェア分析（上位5社およびその他- 金額別、2024年）
• 2024年の市場マップ分析

第6章 北米の自閉症スペクトラム障害治療市場の見通し、2018年～2032年

• 市場規模分析と予測
• 市場シェア分析と予測
• 国別市場評価
  • 米国
  • カナダ
  • メキシコ

第7章 欧州の自閉症スペクトラム障害治療市場の見通し、2018年～2032年

• ドイツ
• フランス
• イタリア
• 英国
• ロシア
• オランダ
• スペイン
• トルコ
• ポーランド

第8章 アジア太平洋の自閉症スペクトラム障害治療市場の見通し、2018年～2032年

• インド
• 中国
• 日本
• オーストラリア
• ベトナム
• 韓国
• インドネシア
• フィリピン

第9章 南米の自閉症スペクトラム障害治療市場の見通し、2018年～2032年

• ブラジル
• アルゼンチン

第10章 中東・アフリカの自閉症スペクトラム障害治療市場の見通し、2018年～2032年

• サウジアラビア
• アラブ首長国連邦
• 南アフリカ

第11章 需要供給分析

第12章 バリューチェーン分析

第13章 ポーターのファイブフォース分析

第14章 PESTLE分析

第15章 価格分析

第16章 市場力学

• 市場の促進要因
• 市場の課題

第17章 市場動向と発展

第18章 規制枠組みとイノベーション

• 規制当局の承認
• 臨床試験

第19章 特許の情勢

第20章 ケーススタディ

第21章 競合情勢

• 市場リーダートップ5の競合マトリックス
• 参入企業トップ5のSWOT分析
• 市場の主要企業トップ10の情勢
  • Curemark LLC
  • Novartis AG
  • Eli Lilly and Company
  • Pfizer Inc.
  • Johnson & Johnson Services Inc.
  • Otsuka Pharmaceutical Co., Ltd.
  • Axial Therapeutics Inc.
  • Bristol-Myers Squibb Company
  • Merck & Co., Inc.
  • F. Hoffmann-La Roche Ltd.

第22章 戦略的提言

第23章 調査会社について・免責事項

List of Tables

• Table 1. Competition Matrix of Top 5 Market Leaders
• Table 2. Mergers & Acquisitions/ Joint Ventures (If Applicable)
• Table 3. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

• Figure 1. Global Autism Spectrum Disorder Treatment Market, By Value, In USD Billion, 2018-2032F
• Figure 2. Global Autism Spectrum Disorder Treatment Market Share (%), By Drug Type, 2018-2032F
• Figure 3. Global Autism Spectrum Disorder Treatment Market Share (%), By Application, 2018-2032F
• Figure 4. Global Autism Spectrum Disorder Treatment Market Share (%), By Distribution Channel, 2018-2032F
• Figure 5. Global Autism Spectrum Disorder Treatment Market Share (%), By Region, 2018-2032F
• Figure 6. North America Autism Spectrum Disorder Treatment Market, By Value, In USD Billion, 2018-2032F
• Figure 7. North America Autism Spectrum Disorder Treatment Market Share (%), By Drug Type, 2018-2032F
• Figure 8. North America Autism Spectrum Disorder Treatment Market Share (%), By Application, 2018-2032F
• Figure 9. North America Autism Spectrum Disorder Treatment Market Share (%), By Distribution Channel, 2018-2032F
• Figure 10. North America Autism Spectrum Disorder Treatment Market Share (%), By Country, 2018-2032F
• Figure 11. United States Autism Spectrum Disorder Treatment Market, By Value, In USD Billion, 2018-2032F
• Figure 12. United States Autism Spectrum Disorder Treatment Market Share (%), By Drug Type, 2018-2032F
• Figure 13. United States Autism Spectrum Disorder Treatment Market Share (%), By Application, 2018-2032F
• Figure 14. United States Autism Spectrum Disorder Treatment Market Share (%), By Distribution Channel, 2018-2032F
• Figure 15. Canada Autism Spectrum Disorder Treatment Market, By Value, In USD Billion, 2018-2032F
• Figure 16. Canada Autism Spectrum Disorder Treatment Market Share (%), By Drug Type, 2018-2032F
• Figure 17. Canada Autism Spectrum Disorder Treatment Market Share (%), By Application, 2018-2032F
• Figure 18. Canada Autism Spectrum Disorder Treatment Market Share (%), By Distribution Channel, 2018-2032F
• Figure 19. Mexico Autism Spectrum Disorder Treatment Market, By Value, In USD Billion, 2018-2032F
• Figure 20. Mexico Autism Spectrum Disorder Treatment Market Share (%), By Drug Type, 2018-2032F
• Figure 21. Mexico Autism Spectrum Disorder Treatment Market Share (%), By Application, 2018-2032F
• Figure 22. Mexico Autism Spectrum Disorder Treatment Market Share (%), By Distribution Channel, 2018-2032F
• Figure 23. Europe Autism Spectrum Disorder Treatment Market, By Value, In USD Billion, 2018-2032F
• Figure 24. Europe Autism Spectrum Disorder Treatment Market Share (%), By Drug Type, 2018-2032F
• Figure 25. Europe Autism Spectrum Disorder Treatment Market Share (%), By Application, 2018-2032F
• Figure 26. Europe Autism Spectrum Disorder Treatment Market Share (%), By Distribution Channel, 2018-2032F
• Figure 27. Europe Autism Spectrum Disorder Treatment Market Share (%), By Country, 2018-2032F
• Figure 28. Germany Autism Spectrum Disorder Treatment Market, By Value, In USD Billion, 2018-2032F
• Figure 29. Germany Autism Spectrum Disorder Treatment Market Share (%), By Drug Type, 2018-2032F
• Figure 30. Germany Autism Spectrum Disorder Treatment Market Share (%), By Application, 2018-2032F
• Figure 31. Germany Autism Spectrum Disorder Treatment Market Share (%), By Distribution Channel, 2018-2032F
• Figure 32. France Autism Spectrum Disorder Treatment Market, By Value, In USD Billion, 2018-2032F
• Figure 33. France Autism Spectrum Disorder Treatment Market Share (%), By Drug Type, 2018-2032F
• Figure 34. France Autism Spectrum Disorder Treatment Market Share (%), By Application, 2018-2032F
• Figure 35. France Autism Spectrum Disorder Treatment Market Share (%), By Distribution Channel, 2018-2032F
• Figure 36. Italy Autism Spectrum Disorder Treatment Market, By Value, In USD Billion, 2018-2032F
• Figure 37. Italy Autism Spectrum Disorder Treatment Market Share (%), By Drug Type, 2018-2032F
• Figure 38. Italy Autism Spectrum Disorder Treatment Market Share (%), By Application, 2018-2032F
• Figure 39. Italy Autism Spectrum Disorder Treatment Market Share (%), By Distribution Channel, 2018-2032F
• Figure 40. United Kingdom Autism Spectrum Disorder Treatment Market, By Value, In USD Billion, 2018-2032F
• Figure 41. United Kingdom Autism Spectrum Disorder Treatment Market Share (%), By Drug Type, 2018-2032F
• Figure 42. United Kingdom Autism Spectrum Disorder Treatment Market Share (%), By Application, 2018-2032F
• Figure 43. United Kingdom Autism Spectrum Disorder Treatment Market Share (%), By Distribution Channel, 2018-2032F
• Figure 44. Russia Autism Spectrum Disorder Treatment Market, By Value, In USD Billion, 2018-2032F
• Figure 45. Russia Autism Spectrum Disorder Treatment Market Share (%), By Drug Type, 2018-2032F
• Figure 46. Russia Autism Spectrum Disorder Treatment Market Share (%), By Application, 2018-2032F
• Figure 47. Russia Autism Spectrum Disorder Treatment Market Share (%), By Distribution Channel, 2018-2032F
• Figure 48. Netherlands Autism Spectrum Disorder Treatment Market, By Value, In USD Billion, 2018-2032F
• Figure 49. Netherlands Autism Spectrum Disorder Treatment Market Share (%), By Drug Type, 2018-2032F
• Figure 50. Netherlands Autism Spectrum Disorder Treatment Market Share (%), By Application, 2018-2032F
• Figure 51. Netherlands Autism Spectrum Disorder Treatment Market Share (%), By Distribution Channel, 2018-2032F
• Figure 52. Spain Autism Spectrum Disorder Treatment Market, By Value, In USD Billion, 2018-2032F
• Figure 53. Spain Autism Spectrum Disorder Treatment Market Share (%), By Drug Type, 2018-2032F
• Figure 54. Spain Autism Spectrum Disorder Treatment Market Share (%), By Application, 2018-2032F
• Figure 55. Spain Autism Spectrum Disorder Treatment Market Share (%), By Distribution Channel, 2018-2032F
• Figure 56. Turkey Autism Spectrum Disorder Treatment Market, By Value, In USD Billion, 2018-2032F
• Figure 57. Turkey Autism Spectrum Disorder Treatment Market Share (%), By Drug Type, 2018-2032F
• Figure 58. Turkey Autism Spectrum Disorder Treatment Market Share (%), By Application, 2018-2032F
• Figure 59. Turkey Autism Spectrum Disorder Treatment Market Share (%), By Distribution Channel, 2018-2032F
• Figure 60. Poland Autism Spectrum Disorder Treatment Market, By Value, In USD Billion, 2018-2032F
• Figure 61. Poland Autism Spectrum Disorder Treatment Market Share (%), By Drug Type, 2018-2032F
• Figure 62. Poland Autism Spectrum Disorder Treatment Market Share (%), By Application, 2018-2032F
• Figure 63. Poland Autism Spectrum Disorder Treatment Market Share (%), By Distribution Channel, 2018-2032F
• Figure 64. South America Autism Spectrum Disorder Treatment Market, By Value, In USD Billion, 2018-2032F
• Figure 65. South America Autism Spectrum Disorder Treatment Market Share (%), By Drug Type, 2018-2032F
• Figure 66. South America Autism Spectrum Disorder Treatment Market Share (%), By Application, 2018-2032F
• Figure 67. South America Autism Spectrum Disorder Treatment Market Share (%), By Distribution Channel, 2018-2032F
• Figure 68. South America Autism Spectrum Disorder Treatment Market Share (%), By Country, 2018-2032F
• Figure 69. Brazil Autism Spectrum Disorder Treatment Market, By Value, In USD Billion, 2018-2032F
• Figure 70. Brazil Autism Spectrum Disorder Treatment Market Share (%), By Drug Type, 2018-2032F
• Figure 71. Brazil Autism Spectrum Disorder Treatment Market Share (%), By Application, 2018-2032F
• Figure 72. Brazil Autism Spectrum Disorder Treatment Market Share (%), By Distribution Channel, 2018-2032F
• Figure 73. Argentina Autism Spectrum Disorder Treatment Market, By Value, In USD Billion, 2018-2032F
• Figure 74. Argentina Autism Spectrum Disorder Treatment Market Share (%), By Drug Type, 2018-2032F
• Figure 75. Argentina Autism Spectrum Disorder Treatment Market Share (%), By Application, 2018-2032F
• Figure 76. Argentina Autism Spectrum Disorder Treatment Market Share (%), By Distribution Channel, 2018-2032F
• Figure 77. Asia-Pacific Autism Spectrum Disorder Treatment Market, By Value, In USD Billion, 2018-2032F
• Figure 78. Asia-Pacific Autism Spectrum Disorder Treatment Market Share (%), By Drug Type, 2018-2032F
• Figure 79. Asia-Pacific Autism Spectrum Disorder Treatment Market Share (%), By Application, 2018-2032F
• Figure 80. Asia-Pacific Autism Spectrum Disorder Treatment Market Share (%), By Distribution Channel, 2018-2032F
• Figure 81. Asia-Pacific Autism Spectrum Disorder Treatment Market Share (%), By Country, 2018-2032F
• Figure 82. India Autism Spectrum Disorder Treatment Market, By Value, In USD Billion, 2018-2032F
• Figure 83. India Autism Spectrum Disorder Treatment Market Share (%), By Drug Type, 2018-2032F
• Figure 84. India Autism Spectrum Disorder Treatment Market Share (%), By Application, 2018-2032F
• Figure 85. India Autism Spectrum Disorder Treatment Market Share (%), By Distribution Channel, 2018-2032F
• Figure 86. China Autism Spectrum Disorder Treatment Market, By Value, In USD Billion, 2018-2032F
• Figure 87. China Autism Spectrum Disorder Treatment Market Share (%), By Drug Type, 2018-2032F
• Figure 88. China Autism Spectrum Disorder Treatment Market Share (%), By Application, 2018-2032F
• Figure 89. China Autism Spectrum Disorder Treatment Market Share (%), By Distribution Channel, 2018-2032F
• Figure 90. Japan Autism Spectrum Disorder Treatment Market, By Value, In USD Billion, 2018-2032F
• Figure 91. Japan Autism Spectrum Disorder Treatment Market Share (%), By Drug Type, 2018-2032F
• Figure 92. Japan Autism Spectrum Disorder Treatment Market Share (%), By Application, 2018-2032F
• Figure 93. Japan Autism Spectrum Disorder Treatment Market Share (%), By Distribution Channel, 2018-2032F
• Figure 94. Australia Autism Spectrum Disorder Treatment Market, By Value, In USD Billion, 2018-2032F
• Figure 95. Australia Autism Spectrum Disorder Treatment Market Share (%), By Drug Type, 2018-2032F
• Figure 96. Australia Autism Spectrum Disorder Treatment Market Share (%), By Application, 2018-2032F
• Figure 97. Australia Autism Spectrum Disorder Treatment Market Share (%), By Distribution Channel, 2018-2032F
• Figure 98. Vietnam Autism Spectrum Disorder Treatment Market, By Value, In USD Billion, 2018-2032F
• Figure 99. Vietnam Autism Spectrum Disorder Treatment Market Share (%), By Drug Type, 2018-2032F
• Figure 100. Vietnam Autism Spectrum Disorder Treatment Market Share (%), By Application, 2018-2032F
• Figure 101. Vietnam Autism Spectrum Disorder Treatment Market Share (%), By Distribution Channel, 2018-2032F
• Figure 102. South Korea Autism Spectrum Disorder Treatment Market, By Value, In USD Billion, 2018-2032F
• Figure 103. South Korea Autism Spectrum Disorder Treatment Market Share (%), By Drug Type, 2018-2032F
• Figure 104. South Korea Autism Spectrum Disorder Treatment Market Share (%), By Application, 2018-2032F
• Figure 105. South Korea Autism Spectrum Disorder Treatment Market Share (%), By Distribution Channel, 2018-2032F
• Figure 106. Indonesia Autism Spectrum Disorder Treatment Market, By Value, In USD Billion, 2018-2032F
• Figure 107. Indonesia Autism Spectrum Disorder Treatment Market Share (%), By Drug Type, 2018-2032F
• Figure 108. Indonesia Autism Spectrum Disorder Treatment Market Share (%), By Application, 2018-2032F
• Figure 109. Indonesia Autism Spectrum Disorder Treatment Market Share (%), By Distribution Channel, 2018-2032F
• Figure 110. Philippines Autism Spectrum Disorder Treatment Market, By Value, In USD Billion, 2018-2032F
• Figure 111. Philippines Autism Spectrum Disorder Treatment Market Share (%), By Drug Type, 2018-2032F
• Figure 112. Philippines Autism Spectrum Disorder Treatment Market Share (%), By Application, 2018-2032F
• Figure 113. Philippines Autism Spectrum Disorder Treatment Market Share (%), By Distribution Channel, 2018-2032F
• Figure 114. Middle East & Africa Autism Spectrum Disorder Treatment Market, By Value, In USD Billion, 2018-2032F
• Figure 115. Middle East & Africa Autism Spectrum Disorder Treatment Market Share (%), By Drug Type, 2018-2032F
• Figure 116. Middle East & Africa Autism Spectrum Disorder Treatment Market Share (%), By Application, 2018-2032F
• Figure 117. Middle East & Africa Autism Spectrum Disorder Treatment Market Share (%), By Distribution Channel, 2018-2032F
• Figure 118. Middle East & Africa Autism Spectrum Disorder Treatment Market Share (%), By Country, 2018-2032F
• Figure 119. Saudi Arabia Autism Spectrum Disorder Treatment Market, By Value, In USD Billion, 2018-2032F
• Figure 120. Saudi Arabia Autism Spectrum Disorder Treatment Market Share (%), By Drug Type, 2018-2032F
• Figure 121. Saudi Arabia Autism Spectrum Disorder Treatment Market Share (%), By Application, 2018-2032F
• Figure 122. Saudi Arabia Autism Spectrum Disorder Treatment Market Share (%), By Distribution Channel, 2018-2032F
• Figure 123. UAE Autism Spectrum Disorder Treatment Market, By Value, In USD Billion, 2018-2032F
• Figure 124. UAE Autism Spectrum Disorder Treatment Market Share (%), By Drug Type, 2018-2032F
• Figure 125. UAE Autism Spectrum Disorder Treatment Market Share (%), By Application, 2018-2032F
• Figure 126. UAE Autism Spectrum Disorder Treatment Market Share (%), By Distribution Channel, 2018-2032F
• Figure 127. South Africa Autism Spectrum Disorder Treatment Market, By Value, In USD Billion, 2018-2032F
• Figure 128. South Africa Autism Spectrum Disorder Treatment Market Share (%), By Drug Type, 2018-2032F
• Figure 129. South Africa Autism Spectrum Disorder Treatment Market Share (%), By Application, 2018-2032F
• Figure 130. South Africa Autism Spectrum Disorder Treatment Market Share (%), By Distribution Channel, 2018-2032F
• Figure 131. By Drug Type Map-Market Size (USD Billion) & Growth Rate (%), 2024
• Figure 132. By Application Map-Market Size (USD Billion) & Growth Rate (%), 2024
• Figure 133. By Distribution Channel Map-Market Size (USD Billion) & Growth Rate (%), 2024
• Figure 134. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2024

Global autism spectrum disorder (ASD) treatment market is projected to witness a CAGR of 6.87% during the forecast period 2025-2032, growing from USD 2.30 billion in 2024 to USD 3.91 billion in 2032. The market is being driven by increasing awareness and early diagnosis of autism spectrum disorder (ASD), prompting a rise in treatment demand. Advancements in drug research and clinical trials are expanding therapeutic options for both core and associated symptoms. Additionally, growing pediatric cases and strong regional support in North America continue to fuel market expansion.

For instance, in June 2024, PaxMedica plans to file a new drug application (NDA) with the U.S. Food and Drug Administration (FDA). By obtaining FDA approval for its innovative drug PAX-101, the company seeks to gain a substantial presence in a market characterized by considerable unmet medical needs. This approach is anticipated to enhance the value of the company's business portfolio.

Increasing Awareness and Early Diagnosis Drives Market Growth

The global autism spectrum disorder (ASD) treatment market is expanding significantly, driven by growing public awareness and advancements in early diagnosis. Early detection of ASD allows timely medical intervention, which is crucial for improving long-term outcomes. Governments, healthcare organizations, and advocacy groups are actively launching campaigns to promote autism awareness and early screening in schools, pediatric settings, and communities. This growing visibility reduces stigma and encourages more parents to seek medical evaluation for developmental delays. Moreover, digital tools and standardized screening protocols have enabled pediatricians and neurologists to identify ASD at an earlier age. The increased focus on developmental health has led to a higher diagnosis rate, particularly in developed regions. As a result, demand for both pharmacological and behavioral therapies is surging. For instance, in April 2025, the World Health Organization announced a global initiative to enhance autism awareness and promote early intervention strategies, aiming to equip member countries with tools and training to detect and manage ASD in children.

Advancements in Drug Research and Pipeline Expansion

Significant investments in research and development (R&D) for autism-specific therapies are propelling the market forward. While current pharmacological options primarily address associated symptoms like irritability, aggression, or hyperactivity, there is a growing emphasis on disease-modifying treatments. Major pharmaceutical companies are collaborating with biotech firms to develop novel drugs targeting core symptoms of ASD. The use of biomarkers, neuroimaging, and genetic profiling is helping scientists understand the biological underpinnings of autism, leading to more targeted therapies. Additionally, several promising candidates are undergoing clinical trials, reflecting increasing investor confidence in this high-need area. The shift toward precision medicine and the expansion of the drug pipeline are expected to improve treatment outcomes and market profitability. For instance, in September 2023, Axial Therapeutics, Inc. dosed the first patient in its Phase 2b clinical trial for AB-2004, a novel gut-targeted small molecule designed to treat irritability and other behavioral symptoms in ASD. This trial marks a crucial step in developing therapies that address the biological mechanisms of autism.

Growing Demand for Autism Treatments in the Pediatric Population

Children constitute the largest age group affected by autism spectrum disorder, and the increasing incidence among this demographic is a major segmental driver of market growth. ASD typically manifests in early childhood, and the rising number of diagnoses, especially in children aged 2 to 8-has driven demand for medications that alleviate behavioral and emotional symptoms. Pediatric formulations, such as liquid suspensions and chewable tablets, are being developed to improve treatment adherence in young patients. Moreover, as parents and caregivers become more proactive in seeking help for developmental delays, they are turning to pharmacological treatments alongside behavioral therapies. Pharmaceutical companies are investing in child-focused research and trial designs to better understand dosing, safety, and efficacy in younger populations. For instance, in January 2025, the FDA awarded Orphan Drug Designation (ODD) to Capsida Biotherapeutics, Inc. for CAP-002, a pioneering gene therapy targeting STXBP1 disorder, which was developed in partnership with Dr. Mingshan Xue at the Duncan Neurological Research Institute of Texas Children's Hospital.

North America Holds Dominant Position in the Market

North America, particularly the United States, continues to dominate the global ASD treatment market due to a combination of factors including high awareness, established healthcare systems, and substantial investment in R&D. The region benefits from robust insurance coverage, availability of specialized professionals, and a high rate of early diagnoses through routine developmental screenings. In addition, the U.S. FDA has shown regulatory flexibility in fast-tracking autism-related treatments, encouraging pharmaceutical companies to develop innovative solutions. The presence of key market players like Pfizer Inc., Eli Lilly and Company, and Johnson & Johnson Services Inc., coupled with active clinical trials, further supports North America's market leadership. Public and private funding initiatives, including support for inclusive education and behavioral therapy programs, also contribute to the demand for pharmacological treatments.

Future Market Scenario (2025-2032F)

The global autism spectrum disorder (ASD) treatment market is projected to witness substantial growth in the coming years, driven by increasing autism prevalence, rising awareness, and advancements in pharmacological research. The development of targeted therapies and a growing focus on early intervention are expected to create new opportunities for market players. With expanding clinical trials and pipeline drugs aimed at addressing core ASD symptoms, pharmaceutical innovation is set to transform the treatment landscape. Furthermore, government funding, insurance coverage for behavioral and drug therapies, and the expansion of telehealth services are improving access to care. North America will continue to lead the market, while emerging economies in Asia-Pacific are expected to offer lucrative growth prospects due to increasing healthcare investments.

Key Players Landscape and Outlook

The key players in the market are significantly investing in the development of autism spectrum disorder treatment and are utilizing strategies such as mergers, acquisitions, partnerships, and new product launches to improve their services and competitiveness. Such efforts will propel significant growth in the market, allowing large-cap industry players to increase their presence and, therefore, find new opportunities in this market.

For example, in February 2025, DeFloria, Inc., a partnership between Ajna BioSciences PBC and Charlotte's Web Holdings, Inc., announced that the U.S. Food and Drug Administration (FDA) has finalized its assessment of the Investigational New Drug (IND) application for AJA001, a multi-cannabinoid botanical drug administered orally. The FDA's conclusion allows the company to advance to its planned Phase 2 clinical trial. DeFloria is working on AJA001 as a potential treatment for symptoms associated with autism spectrum disorder (ASD) and intends to commence the Phase 2 study by the middle of 2025.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Impact of U.S. Tariffs

4. Executive Summary

5. Global Autism Spectrum Disorder Treatment Market Outlook, 2018-2032F

• 5.1. Market Size Analysis & Forecast
  • 5.1.1. By Value
• 5.2. Market Share Analysis & Forecast
  • 5.2.1. By Drug Type
    • 5.2.1.1. Antipsychotic Drugs
    • 5.2.1.2. Selective Serotonin Reuptake Inhibitors
    • 5.2.1.3. Stimulants
    • 5.2.1.4. Sleep Medications
    • 5.2.1.5. Others
  • 5.2.2. By Application
    • 5.2.2.1. Autistic Disorder
    • 5.2.2.2. Asperger Syndrome
    • 5.2.2.3. Pervasive Developmental Disorder
    • 5.2.2.4. Others
  • 5.2.3. By Distribution Channel
    • 5.2.3.1. Hospital Pharmacies
    • 5.2.3.2. Retail Pharmacies
    • 5.2.3.3. Online Pharmacies
  • 5.2.4. By Region
    • 5.2.4.1. North America
    • 5.2.4.2. Europe
    • 5.2.4.3. Asia-Pacific
    • 5.2.4.4. South America
    • 5.2.4.5. Middle East and Africa
  • 5.2.5. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2024)
• 5.3. Market Map Analysis, 2024
  • 5.3.1. By Drug Type
  • 5.3.2. By Application
  • 5.3.3. By Distribution Channel
  • 5.3.4. By Region

6. North America Autism Spectrum Disorder Treatment Market Outlook, 2018-2032F

• 6.1. Market Size Analysis & Forecast
  • 6.1.1. By Value
• 6.2. Market Share Analysis & Forecast
  • 6.2.1. By Drug Type
    • 6.2.1.1. Antipsychotic Drugs
    • 6.2.1.2. Selective Serotonin Reuptake Inhibitors
    • 6.2.1.3. Stimulants
    • 6.2.1.4. Sleep Medications
    • 6.2.1.5. Others
  • 6.2.2. By Application
    • 6.2.2.1. Autistic Disorder
    • 6.2.2.2. Asperger Syndrome
    • 6.2.2.3. Pervasive Developmental Disorder
    • 6.2.2.4. Others
  • 6.2.3. By Distribution Channel
    • 6.2.3.1. Hospital Pharmacies
    • 6.2.3.2. Retail Pharmacies
    • 6.2.3.3. Online Pharmacies
  • 6.2.4. By Country Share
    • 6.2.4.1. United States
    • 6.2.4.2. Canada
    • 6.2.4.3. Mexico
• 6.3. Country Market Assessment
  • 6.3.1. United States Autism Spectrum Disorder Treatment Market Outlook, 2018-2032F*
    • 6.3.1.1. Market Size Analysis & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share Analysis & Forecast
      • 6.3.1.2.1. By Drug Type
        • 6.3.1.2.1.1. Antipsychotic Drugs
        • 6.3.1.2.1.2. Selective Serotonin Reuptake Inhibitors
        • 6.3.1.2.1.3. Stimulants
        • 6.3.1.2.1.4. Sleep Medications
        • 6.3.1.2.1.5. Others
      • 6.3.1.2.2. By Application
        • 6.3.1.2.2.1. Autistic Disorder
        • 6.3.1.2.2.2. Asperger Syndrome
        • 6.3.1.2.2.3. Pervasive Developmental Disorder
        • 6.3.1.2.2.4. Others
      • 6.3.1.2.3. By Distribution Channel
        • 6.3.1.2.3.1. Hospital Pharmacies
        • 6.3.1.2.3.2. Retail Pharmacies
        • 6.3.1.2.3.3. Online Pharmacies
  • 6.3.2. Canada
  • 6.3.3. Mexico

All segments will be provided for all regions and countries covered

7. Europe Autism Spectrum Disorder Treatment Market Outlook, 2018-2032F

• 7.1. Germany
• 7.2. France
• 7.3. Italy
• 7.4. United Kingdom
• 7.5. Russia
• 7.6. Netherlands
• 7.7. Spain
• 7.8. Turkey
• 7.9. Poland

8. Asia-Pacific Autism Spectrum Disorder Treatment Market Outlook, 2018-2032F

• 8.1. India
• 8.2. China
• 8.3. Japan
• 8.4. Australia
• 8.5. Vietnam
• 8.6. South Korea
• 8.7. Indonesia
• 8.8. Philippines

9. South America Autism Spectrum Disorder Treatment Market Outlook, 2018-2032F

• 9.1. Brazil
• 9.2. Argentina

10. Middle East and Africa Autism Spectrum Disorder Treatment Market Outlook, 2018-2032F

• 10.1. Saudi Arabia
• 10.2. UAE
• 10.3. South Africa

11. Demand Supply Analysis

12. Value Chain Analysis

13. Porter's Five Forces Analysis

14. PESTLE Analysis

15. Pricing Analysis

16. Market Dynamics

• 16.1. Market Drivers
• 16.2. Market Challenges

17. Market Trends and Developments

18. Regulatory Framework and Innovation

• 18.1. Regulatory Approvals
• 18.2. Clinical Trials

19. Patent Landscape

20. Case Studies

21. Competitive Landscape

• 21.1. Competition Matrix of Top 5 Market Leaders
• 21.2. SWOT Analysis for Top 5 Players
• 21.3. Key Players Landscape for Top 10 Market Players
  • 21.3.1. Curemark LLC
    • 21.3.1.1. Company Details
    • 21.3.1.2. Key Management Personnel
    • 21.3.1.3. Products and Services
    • 21.3.1.4. Financials (As Reported)
    • 21.3.1.5. Key Market Focus and Geographical Presence
    • 21.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisitions
  • 21.3.2. Novartis AG
  • 21.3.3. Eli Lilly and Company
  • 21.3.4. Pfizer Inc.
  • 21.3.5. Johnson & Johnson Services Inc.
  • 21.3.6. Otsuka Pharmaceutical Co., Ltd.
  • 21.3.7. Axial Therapeutics Inc.
  • 21.3.8. Bristol-Myers Squibb Company
  • 21.3.9. Merck & Co., Inc.
  • 21.3.10. F. Hoffmann-La Roche Ltd.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

22. Strategic Recommendations

23. About Us and Disclaimer